Minimum Bio
- Biotech or pharma, therapeutic R&D
- Other R&D services
MINIMUM bio has developed the Mercurious® platform, a cutting-edge and scalable drug target discovery technology leveraging advanced phage display methodologies. Mercurious rapidly identifies novel, first-in-class drug targets—including previously "undruggable"protein-protein interactions (PPIs)—for small molecules, biologics, and molecular glues, significantly accelerating and de-risking the drug development process.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}